28 computer-algorithm-"Prof" Fellowship positions at Nature Careers in United Kingdom
Sort by
Refine Your Search
-
and innovation (R&I) ecosystem. This is a unique opportunity to establish or expand your research programme in the UK, collaborate with world-class researchers, and contribute to national and global
-
the application process, please contact Biosciences staffing at . About you You must have a PhD (or be studying towards it) in Medical Physics or Bioengineering, Computational Neuroscience, Applied
-
recently funded 5-year programme of antifungal drug discovery at the MRC Centre for Medical Mycology. This exciting new programme connects MRC CMM researchers with drug discovery experts and scientists from
-
joint homeostasis. The successful candidate will work in close association with other lab-based scientists and computational biologists in the Croft lab as well as collaborators in Great Ormond Street
-
the Department of Inflammation and Ageing at the University of Birmingham. The successful candidate will work to deliver high level computational analysis of immune cell subsets in patients with cutaneous lupus
-
performance computing systems in a way that is suitable for operational use. Implement and test different ML architectures, such as convolutional and encoders-decoder ANNs for predicting flooding in Bihar and
-
-cell genomics/computer science (AI), neuroscience, vascular biology, developmental biology, cancer biology, immunology, biology/biomedicine, pharmacy, biomedical engineering, or related fields with ample
-
to formulate and lead a research programme that will deliver innovative, world-class science in molecular host-microbes interactions or a related field and good knowledge of JIC/NRP research fields, underpinning
-
post has arisen to work for 2 years (in the first instance) on a Programme grant joint between UCL, Insititute of Child Health and University of Newcastle entitled INSTINCT-MBINSTINCT MB. The work in the
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic